Post by Deleted on Nov 14, 2015 14:24:04 GMT
You're right, sometimes the presenter does spike before these meetings:
BOTHELL, WA and ATLANTA, GA--(Marketwired - October 15, 2015) - Cocrystal Pharma, Inc. (COCP), a bio-pharmaceutical company dedicated to creating novel small molecules for viral infections and liver diseases, today announced that its late-breaking abstract was accepted for a poster presentation at The Liver Meeting, the annual meeting of the American Association of the Study of Liver Diseases (AASLD) in San Francisco, November 13-17. The abstract, entitled, "Preclinical characterization of CC-31244, a potent, pan-genotypic nonnucleoside NS5B polymerase inhibitor (NNI) for the treatment of chronic hepatitis C", will be presented by Dr. Sam Lee, President, on Monday the 16th at 12:30 pm. The abstract is available after October 20th at www.aasld.org/.
In the abstract, Cocrystal disclosed the genotype coverage, in vitro and preclinical properties of a novel NNI inhibitor, CC-31244
"We are encouraged by the CC-31244 preclinical profile and the opportunity to develop a novel, pan-genotypic NNI. Cocrystal is working to transition into a clinical company and excited about the numerous antiviral programs we are currently developing," said Dr. Douglas Mayers, Cocrystal Pharma Chief Medical Officer.